SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives

SALT LAKE CITY, Utah, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today provided a business update in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

During the first half of 2026, SINTX advanced the commercialization of its FDA-cleared SiNAPTIC(®) Foot & Ankle Implant System, expanded its commercial distribution network, raised additional capital, invested in advanced manufacturing capabilities, and continued to broaden the application of its proprietary silicon nitride technology platform across multiple healthcare and industrial markets.